A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder
Phase of Trial: Phase III/IV
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Aripiprazole (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 30 Oct 2018 Status changed from not yet recruiting to recruiting.
- 03 Oct 2018 Planned initiation date changed from 28 Sep 2018 to 31 Oct 2018.
- 19 Sep 2018 Planned initiation date changed from 19 Sep 2018 to 28 Sep 2018.